Overview

ENTRUST, a 5 Year Surveillance of Children Aged 2 to <6 Years With Transfusional Iron Overload Treated With Deferasirox

Status:
Completed
Trial end date:
2015-07-01
Target enrollment:
0
Participant gender:
All
Summary
This registry will evaluate long-term safety and efficacy of deferasirox in children with transfusional iron overload.
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Deferasirox
Criteria
Inclusion Criteria:

- History of transfusion-dependent anemia.

- History of iron overload

Exclusion Criteria:

- Patients with non-transfusional hemosiderosis.

Other protocol-defined inclusion/exclusion criteria may apply.